Medtech Firm Cardialen to Kick Off Fifth Clinical Trial
Cardialen president and CEO Jeff Peters Cardialen Inc.

Medtech Firm Cardialen to Kick Off Fifth Clinical Trial

The company is developing a new treatment for irregular heartbeats in heart failure patients.

Minneapolis-based medtech company Cardialen Inc. is set to begin the fifth clinical trial of a new treatment for irregular heartbeats in heart failure patients.

Last week, the company announced that it has received approval from the U.S. Food and Drug Administration to begin a clinical trial of a new process known as “MultiPulse Therapy.” Cardialen’s technology would work in concert with existing implantable heart failure devices on the market, says CEO and president Jeff Peters.

Medtronic, Abbott, and Boston Scientific are among the bigger names in the heart failure device market. But none of those companies’ existing heart failure devices treat atrial fibrillation, or irregular and sometimes dangerous heartbeats.

“We’re developing this therapy that we believe could be incorporated into current products,” Peters says.

Cardialen’s technology works by administering low-energy electrical pulses to help stabilize and regulate heartbeats. That’s essentially how modern defibrillators work, but those use a higher-energy jolt of electricity that can be painful for patients, Peters notes. Cardialen’s therapy is designed to be “pain tolerable” to patients, he says.

He likens the process to resolving a buggy mobile app on a phone: Instead of restarting the phone entirely, it’s a matter of restarting the app.

Peters notes that he’s been in talks with heart failure device makers, and that he expects to partner with at least one of them by 2022.

Meanwhile, Cardialen has already embarked on four other patient studies: two in the United States and two in Australia. The fifth study will also take place in the U.S. Cardialen kicked off its “first-in-human trials” in April of this year. Peters said it’s “unusual for a company our size” to take on that many clinical trials at once.

If the company’s technology proves successful in the clinical trials, Peters believes it would become “another important tool” for heart failure patients.

In late 2018, Cardialen closed on a $17 million Series B raise, bringing its total investment to around $30 million at the time. In September, the company landed another $3 million from the National Institutes of Health. Cardialen is still in the pre-revenue stage, but Peters said he’s not actively pursuing additional investments at this time.